Investigational drug vupanorsen reduces non-HDL cholesterol by up to 28%

By | April 3, 2022
The investigational drug vupanorsen reduced total levels of non-high-density lipoprotein (non-HDL) cholesterol by up to 28% in patients with high cholesterol who were already taking a cholesterol-lowering statin medication, in a study presented at the American College of Cardiology’s 71st Annual Scientific Session.